Vytorin Takes Low Road To Higher Ground: Lower LDL Is Key To Growth
Executive Summary
Schering-Plough sees positioning Vytorin as the preferred cholesterol therapy for achieving lower LDL levels as the key to future growth
You may also be interested in...
Rising Drug Use Stems From Changes In Clinical Guidelines – PhRMA Report
Increased use of drugs for high cholesterol is partly due to a paradigm shift from an initial approach of diet and exercise towards starting patients on drug therapy as the first course of action, according to a study on the increased use of medication for chronic conditions co-sponsored by the Pharmaceutical Research & Manufacturers of America and the Disease Management Association of America
Rising Drug Use Stems From Changes In Clinical Guidelines – PhRMA Report
Increased use of drugs for high cholesterol is partly due to a paradigm shift from an initial approach of diet and exercise towards starting patients on drug therapy as the first course of action, according to a study on the increased use of medication for chronic conditions co-sponsored by the Pharmaceutical Research & Manufacturers of America and the Disease Management Association of America
Joint Venture On The Rocks? Schering Looks To Compete With Partner Merck
Schering-Plough is exploring opportunities to add Zetia (ezetimibe) to an agent that would give the treatment an entrance into the growing HDL-cholesterol category